Holen Sie sich die Stockscreener-App
126.30
1.05%
-1.34
Handel nachbörslich:
126.32
0.02
+0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$127.64
Offen:
$127.95
24-Stunden-Volumen:
7.64M
Relative Volume:
1.29
Marktkapitalisierung:
$219.05B
Einnahmen:
$41.95B
Nettoeinkommen (Verlust:
$13.40B
KGV:
16.51
EPS:
7.65
Netto-Cashflow:
$6.35B
1W Leistung:
-4.79%
1M Leistung:
-2.98%
6M Leistung:
+9.94%
1J Leistung:
+12.33%
1-Tages-Spanne:
$124.90
$128.62
1-Wochen-Bereich:
$124.50
$132.61
52-Wochen-Spanne:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.30 | 219.05B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
99.22 | 146.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
375.91 | 143.44B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.21 | 118.24B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.34 | 41.35B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
US health agencies announce plan to strengthen infant formula supply and quality -March 18, 2025 at 02:23 pm EDT - Marketscreener.com
Abbott Laboratories (ABT): Among the Best Diabetes Stocks to Buy According to Billionaires - Insider Monkey
Decoding Abbott Laboratories's Options Activity: What's the Big Picture? - Benzinga
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views? - Nasdaq
Personalized Vitamins Market Top Players- BASF SE, Abbott Laboratories. Amway Corporation, Bayer AG, Caligenix. - openPR
Abbott's Narrow Economic Moat Rests on a Solid Product Portfolio - Morningstar
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock? - Yahoo Finance
Blood Typing Analysis Report 2024: Market Set to Surge to $6.50 Billion by 2034, PCR and Microarray Techniques Pave the Way - GlobeNewswire Inc.
Abbott Stock Could Be On The Verge Of A Breakout — Here’s What Smart Money Sees (NYSE:ABT) - Seeking Alpha
Reckitt’s Mead Johnson, Abbott to face new trial in US infant-formula case - just-food.com
Abbott Laboratories Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) earnings growth rate lags the 15% CAGR delivered to shareholders - Simply Wall St
Abbott Laboratories Basking In A Sharp Turn In Sentiment (NYSE:ABT) - Seeking Alpha
Why Abbott Laboratories (ABT) Went Down On Thursday? - MSN
Why Abbott Laboratories (ABT) Went Down On Friday? - Insider Monkey
Abbott Labs, Reckitt Benckiser Shares Fall After New Ruling on Infant Formula Case - The Wall Street Journal
Baby Formula Makers Abbott and Reckitt See Stocks Slide as Judge Allows Retrial - Investopedia
In a setback for Abbott Laboratories, judge allows new trial in case over formula for premature infants - Chicago Tribune
Judge Vacates Baby Formula Trial Win For Abbott, Mead - Law360
‘A Manifest Injustice': Judge Who Sanctioned Abbott’s Counsel Grants New Infant Formula Trial - Law.com
Sector Update: Health Care -March 14, 2025 at 03:29 pm EDT - Marketscreener.com
BofA keeps $150 target on Abbott Labs stock amid retrial news - Investing.com
Abbott, Reckitt Fall as Judge Grants New Trial on Infant Formula - Bloomberg
Abbott, Reckitt face new trial over premature infant formula - Reuters
That baby formula trial Abbott and Reckitt won isn't over just yet - Crain's Chicago Business
Judge orders retrial in Abbott, Reckitt infant formula case - Seeking Alpha
Citi maintains Abbott stock Buy rating, $160 target amid legal updates By Investing.com - Investing.com South Africa
Is Abbott Laboratories (ABT) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Citi maintains Abbott stock Buy rating, $160 target amid legal updates - Investing.com
Abbott, Reckitt face new trial over premature infant formula -March 14, 2025 at 11:09 am EDT - Marketscreener.com
Positive Long-Term Outlook for Abbott Laboratories Despite Short-Term NEC Litigation Risks - TipRanks
Abbott sends film crew to highlight partnership with Auburn Community Hospital - The Citizen
Abbott stock falls following retrial order in infant formula case - Investing.com
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Abbott (ABT) Stock Moves -0.3%: What You Should Know - Nasdaq
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - MSN
Abbott (ABT) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Glucose Biosensor Market Booming with Technological Advancements | Industry Insights Abbott Laboratories, - EIN News
Here's Why We Think Abbott Laboratories (NYSE:ABT) Might Deserve Your Attention Today - Yahoo Finance
OTC Consumer Health Market Positioned for Accelerated Growth with Johnson&Johnson, Abbott Laboratories, - EIN News
EPD Expansion Supports Abbot Stock, Macro Issues Prevail - TradingView
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
Abbott Laboratories (NYSE:ABT) Given New $150.00 Price Target at Bank of America - Defense World
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment - Benzinga
BofA Raises Price Target on Abbott Laboratories to $150 From $133 -March 10, 2025 at 10:06 am EDT - Marketscreener.com
Electroceutical Devices Market Projected To Witness Substantial Growth, 2025-2032: Medtronic plc, Abbott - EIN News
Abbott Laboratories Stock Analysis: Short-Term Gains vs. Long-Term ChallengesNews and Statistics - IndexBox, Inc.
3 Reasons to Avoid ABT and 1 Stock to Buy Instead - Yahoo Finance
Cancer Diagnostics Market Top PlayersGE Healthcare, Abbott - openPR
Shedd Aquarium receives $10 million pledge from Abbott - Philanthropy News Digest
Lisa D. Earnhardt Sells 91,167 Shares of Abbott Laboratories (NYSE:ABT) Stock - Defense World
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.32%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):